Experiment documents that weight-loss-drug users are judged more harshly

A new experiment published in the October 2026 issue of Social Science & Medicine finds that people judge the same person differently depending on how she lost weight — and that using a weight-loss medication drew the harshest judgment ^[1].

Researchers Madelyn H. Rosenthal and Mary S. Himmelstein randomly assigned 297 participants to read one of three short vignettes about a woman named "Alex" who lost weight and later regained it. The only thing that changed between versions was the method: bariatric surgery, a common weight-loss medication (Ozempic, the brand name for semaglutide), or behavior modification through diet and exercise alone ^[1].

Participants then answered questionnaires about their beliefs and attitudes toward Alex, toward body weight generally, and toward different weight-loss strategies. The result: Alex was viewed more negatively and assumed to be less healthy when she lost weight with Ozempic than when she lost it through diet and exercise alone ^[1].

Notably, there were no statistically detectable differences in how Alex was viewed when she had bariatric surgery compared with either of the other two methods ^[1]. That runs against some expectations, since prior research had suggested that people who undergo bariatric surgery face "compounding prejudice" from both their body size and the surgery itself, with the operation often framed as "taking the easy way out" ^[1]. The authors note that no previous study had directly compared attitudes toward surgery versus weight-loss drugs, making this the first head-to-head experimental test ^[1].

What else the study found

Beyond the judgment of Alex, the survey turned up broad gaps in what participants understood about weight management. The authors report that people "drastically" underestimated how common weight regain is and misjudged how effective various weight-management strategies actually are ^[1].

The sample skewed young and female: 78.8% of participants were women, average age was 20.2 years, and 42.4% had a BMI above 25.0 kg/m² ^[1]. The researchers reported no conflicts of interest and said the work received no specific grant from public, commercial, or nonprofit funders ^[1].

Some details are not available from the published abstract, including the exact size of the differences in ratings, the specific questionnaires used, how participants were recruited, and the precise wording of each vignette ^[1]. Readers who want those specifics would need the full open-access paper.

Why it matters for patients

Many people taking semaglutide or other GLP-1 medications already describe hiding it from coworkers, friends, or family. This study puts a controlled experiment behind that experience: when everything else about a person is held identical, naming a weight-loss drug as the method shifted perceptions in a negative direction, including assumptions about the person's health ^[1].

That has practical implications. Stigma can shape whether someone discusses a medication with a clinician, whether they feel comfortable being open about side effects, and how they're treated if weight returns. The study also underscores a second issue: participants badly underestimated how common weight regain is across all methods ^[1]. If the general public assumes weight loss is usually permanent, someone who regains weight — on any strategy — may face blame that the evidence doesn't support.

The authors frame this as an argument for better public information, writing that the findings highlight the need for "empirically informed information on body weight in public health" along with strategies to reduce weight stigma ^[1].

One important caveat: the participants were mostly young women with an average age of about 20 ^[1]. Whether the same pattern holds among older adults, men, employers, or health care providers was not tested here and is not yet known.